Product availability may vary by country; associated claims do not constitute medical claims and may differ based on government requirements.
By binding pathogenic bacteria, NeutraPath reduces pathogen colonization of the gastrointestinal tract. However, NeutraPath also has multiple bactericidal and bacteriostatic effects. For example, by disrupting pH homeostasis and increasing membrane permeability, NeutraPath impairs bacterial cell function and integrity. NeutraPath also compromises pathogen purine integrity and binds to a protein essential for bacterial cell division, both of which prevent bacterial replication.
The virulence of bacterial pathogens is determined by multiple factors, many of which NeutraPath can neutralize. NeutraPath can bind the toxins produced by pathogenic bacteria as well as the quorum-sensing molecules used by bacteria to communicate and coordinate their attack. Virulence genes can also be targeted — in one study, NeutraPath downregulated expression of Salmonella enterica serovar Typhimurium genes that encode the host cell invasion system.
When first ingested, NeutraPath is at or above the minimum inhibitory concentration (MIC). In the upper GI tract, the bactericidal and bacteriostatic effects of NeutraPath target bacterial cell structure and function. In the lower GI tract, NeutraPath’s antivirulence actions provide the main antimicrobial effects.
The antimicrobial effects of NeutraPath allow better absorption of nutrients and improved intestinal health in challenged environments. We have collaborated with leading contract research organizations and well-known universities to prove that these antimicrobial effects of NeutraPath translate into production and health benefits.
Please wait while you are redirected to the right page...